XOMA Corporation (XOMAP) Price Target Analysis
Wall Street analyst price targets, ratings consensus & upside potential
Current Price
$26.06
Price Target
—
Target Range
— — —
Analyst Rating
Buy
Forward P/E39.1x
Trailing P/E-15.8x
Forward PEG—
Implied Growth-44.4%
Median Target—
Analyst Spread—
Price Forecast (1 Year)
Last 12 months price action with 12-month analyst target path
Bear Case
$—
—
Consensus
$—
—
Bull Case
$—
—
XOMAP Price Target Analysis
Updated March 4, 2026As of March 4, 2026, XOMA Corporation (XOMAP) has a Wall Street consensus price target of N/A, based on estimates from 9 covering analysts. The company has a market capitalization of $321M.
Analyst price targets range from a low of N/A to a high of N/A.
The current analyst consensus rating is Buy, with 5 analysts rating the stock as a Buy or Strong Buy,4 rating it Hold, and 0 rating it Sell or Strong Sell. The positive sentiment balance indicates moderate optimism about the stock prospects.
From a valuation perspective, XOMAP trades at a trailing P/E of -15.8x and forward P/E of 39.1x. Analysts expect EPS to grow -44.4% over the next year.
Investment Context: Price targets represent analyst expectations for the next 12 months and should be considered alongside your own research. Targets are based on analysts' assumptions about earnings growth, margins, and market conditions which may change. For sector-specific context, view other Healthcare stocks.
Analyst Sentiment Comparison
Industry Peer AnalysisAvg Peer Upside+92.5%
Avg Forward P/E24.5x
Peers with Coverage5 / 8
| Company | Market Cap | Price | Target | Upside | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
| XOMAPXOMA Corporation | $321M | $26.06 | — | — | Buy | 39.1x | 9 |
 RPRXRoyalty Pharma plc | $7.1B | $47.26 | $49.40 | +4.5% | Buy | 9.7x | 11 |
 LGNDLigand Pharmaceuticals Incorporated | $4.0B | $202.09 | $248.00 | +22.7% | Buy | 23.8x | 16 |
 INVAInnoviva, Inc. | $1.7B | $22.25 | $32.50 | +46.1% | Buy | 11.3x | 10 |
 BTXBlackRock Technology and Private Equity Term Trust | $765M | $6.55 | — | — | — | — | — |
 XOMAXOMA Royalty Corp. | $305M | $25.54 | $68.25 | +167.2% | Buy | 38.3x | 10 |
 CBUSCibus, Inc. | $106M | $3.57 | $11.50 | +222.1% | Buy | — | 3 |
 CDTCDT Equity Inc. | $30M | $0.60 | — | — | — | — | — |
Upside Potential Comparison
CBUSXOMAINVALGNDRPRXSee XOMAP's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs XOMAP Undervalued?
See our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationCompare XOMAP vs AGIO
See how XOMAP stacks up against sector leader Agios Pharmaceuticals, Inc..
Start ComparisonFrequently Asked Questions
What is the XOMAP stock price target for 2026?
The consensus price target for XOMAP is $N/A, close to the current price of $26.056 (N/A% implied move). Based on 9 analyst estimates, the stock appears fairly valued near current levels.
Is XOMAP a buy, sell, or hold?
XOMAP has a consensus rating of "Buy" based on 9 Wall Street analysts. The rating breakdown is predominantly bullish, with 5 Buy/Strong Buy ratings. The consensus 12-month price target of $N/A implies N/A% upside from current levels.
Is XOMAP stock overvalued or undervalued?
At a forward P/E of 39.1231x, XOMAP trades at a premium valuation. The consensus price target of $N/A (N/A% upside) suggests analysts may view current valuations as stretched.
How high can XOMAP stock go?
The most bullish Wall Street analyst has a price target of $N/A for XOMAP, while the most conservative target is $N/A. The consensus of $N/A represents the median expectation. These targets typically reflect 12-month expectations.
How many analysts cover XOMAP stock?
XOMAP is moderately covered, with 9 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 5 have Buy ratings, 4 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
What is the XOMAP stock forecast?
The 12-month XOMAP stock forecast based on 9 Wall Street analysts shows a consensus price target of $N/A, with estimates ranging from $N/A (bear case) to $N/A (bull case). The median consensus rating is "Buy".
What is XOMAP's forward P/E ratio?
XOMAP trades at a forward P/E ratio of 39.1x based on next-twelve-months earnings estimates. The higher forward P/E suggests near-term earnings pressure. A forward P/E is useful for comparing valuations when earnings are expected to change significantly.
Should I buy XOMAP stock?
XOMAP appears fairly valued according to analysts, with a "Buy" rating and minimal upside to the $N/A target. Consider your investment thesis and risk tolerance. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
Why do XOMAP price targets vary so much?
XOMAP analyst price targets range from $N/A to $N/A, a NaN% tight range reflecting strong analyst consensus. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $N/A consensus represents the middle ground.